Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCOUNTS RECEIVABLE (Details)

v3.23.3
SCHEDULE OF ACCOUNTS RECEIVABLE (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Receivables [Abstract]    
CyPath® Lung royalty income $ 16,107 $ 4,803
Laboratory services 12,390
Other receivables 4,730 5,686
Purchased receivables from acquisition, net of collections 791,852
Net patient fees receivable 249,088
Histology fees 31,854
Medical director fees 2,393
Accounts and other receivable, net $ 1,108,414 $ 10,489